Federal Trade Commission Concludes Investigation into Bayer Pharmaceuticals and Yasmin Patent Litigation
Published October 12, 2012 by LawsuitInformation.org In recent news regarding Bayer Pharmaceuticals, the German pharmaceutical giant responsible for the manufacture of Yaz and Yasmin, the Federal Trade Commission made the decision to terminate its investigation into a patent settlement between Bayer and Teva Pharmaceuticals. In 2008, the two pharmaceutical companies reached an agreement in regards to Bayer’s claim that Barr Laboratories, which was ultimately purchased by Teva Pharmaceuticals, overstepped the boundaries of intellectual property protecting Bayer’s Yasmin patent. The 2008 settlement drew the attention of the FTC, and led Continue Reading
Controversy Surrounds the FDA’s Decision to Keep Yaz On the Market
Published June 20, 2012 on LawsuitInformation.org The FDA recently mandated that Bayer Pharmaceuticals change the warning labels on two of its most popular birth control pills to reflect recent research relating to blood clots as a result of Yasmin or Yaz. The decision comes in the midst of many ongoing lawsuits against Bayer and generic Yasmin or Yaz manufacturers relating to side effects resulting from Yaz, and has been met with criticism from watchdog groups and other advocacy groups accusing the FDA of not doing enough. FDA addresses concerns Continue Reading
